C. Audigier-Valette

机构：Hôpital d'Instruction des Armées Sainte-Anne, Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer

发表论文 5 篇 · 总被引 19 次 · h-index 2

代表论文

• OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (2023 · Journal of Thoracic Oncology · 被引 12)
• Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 7)
• MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227 (2024 · Annals of Oncology)
• 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023 · Journal of Thoracic Oncology)
• PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227 (2023 · Journal of Thoracic Oncology)